Quest Diagnostics (DGX) Tops Q4 EPS by 26c, Revenues Beat; Offers FY20 EPS/Revenue Outlook

Quest Diagnostics (NYSE: DGX) reported Q4 EPS of $1.86, $0.26 better than the analyst estimate of $1.60. Revenue for the quarter came in at $1.93 billion versus the consensus estimate of $1.92 billion.

"We had a solid fourth quarter and ended the year by delivering record revenues, earnings and cash from operations," said Steve Rusckowski, Chairman, CEO and President. "Strong volume growth from expanded health plan network access, combined with outstanding execution of our Operational Excellence strategy, helped us offset significant reimbursement pressure.

"Quest is well positioned once again in 2020 to deliver on our commitment to grow revenues and earnings. We have a strong value proposition that supports health care\'s triple aim of improving medical quality and the patient experience while reducing the cost of care. Our guidance for 2020 reflects our continued momentum, partially offset by yet another year of meaningful reimbursement pressure."

GUIDANCE:

Quest Diagnostics sees FY2020 EPS of $6.60, versus the consensus of $6.73. Quest Diagnostics sees FY2020 revenue of $7.8-7.96 billion, versus the consensus of $7.86 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• CMS Energy (CMS) Misses Q1 EPS by 1c ; Offers Guidance
• Quest Diagnostics (DGX) PT Raised to $155 at Mizuho